Financial Performance - The company's revenue for Q3 2022 was CNY 218,470,759.89, an increase of 0.76% year-on-year, while the revenue for the year-to-date period reached CNY 681,150,652.08, up 3.22% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 51,192,368.36, representing a growth of 19.45% year-on-year, and the year-to-date net profit was CNY 130,074,008.87, an increase of 14.61%[4] - The basic earnings per share for Q3 2022 was CNY 0.1017, up 19.37% year-on-year, with diluted earnings per share also at CNY 0.1017[4] - Total operating revenue for the period reached ¥681,150,652.08, an increase of 3.7% compared to ¥659,918,134.34 in the previous period[22] - Net profit attributable to shareholders was ¥130,074,008.87, representing a 14.6% increase from ¥113,492,866.04 year-over-year[23] - Basic and diluted earnings per share increased to ¥0.2585 from ¥0.2255, reflecting a growth of 14.0%[24] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to CNY 2,326,803,516.30, reflecting a growth of 10.21% compared to the end of the previous year[4] - The total assets of the company reached ¥2,326,803,516.30, an increase from ¥2,111,282,192.35 at the beginning of the year, reflecting a growth of 10.2%[20] - The company's accounts receivable rose to ¥244,069,859.79, compared to ¥207,401,998.50 at the start of the year, indicating an increase of 17.6%[20] - The total liabilities rose to ¥454,999,569.04, compared to ¥368,989,659.95 in the previous period, marking a 23.3% increase[23] - The total liabilities include accounts payable of ¥37,720,362.29, down from ¥51,440,181.32, indicating a decrease of 26.7%[20] Cash Flow - Cash flow from operating activities showed a net outflow of CNY 99,673,861.60 year-to-date, a significant decrease of 44.28% compared to the same period last year[4] - Cash flow from operating activities decreased to ¥715,181,968.17 from ¥779,328,523.24, a decline of 8.2%[25] - The net cash flow from operating activities for Q3 2022 was ¥99,673,861.60, a decrease of 44.3% compared to ¥178,868,988.40 in Q3 2021[26] - The total cash inflow from operating activities was ¥727,909,881.30, compared to ¥793,862,474.10 in the same quarter last year[26] - The total cash outflow from operating activities was ¥628,236,019.70, slightly higher than ¥614,993,485.70 in Q3 2021[26] Investments and Financing - The net cash flow from investing activities increased by 59.84% year-on-year, primarily due to an increase in cash received from purchasing bank wealth management and structured deposit products[11] - The net cash flow from financing activities increased by 432.43% year-on-year, mainly due to an increase in cash received from bank loans amounting to CNY 20,000,000[13] - Total cash inflow from investment activities was ¥105,725,650.98, significantly higher than ¥9,451,927.51 in the previous year[26] - The net cash flow from investment activities was -¥60,548,911.08, improving from -¥150,779,901.61 in Q3 2021[26] - Cash inflow from financing activities totaled ¥151,504,745.40, up from ¥130,153,195.20 in the same quarter last year[26] - The net cash flow from financing activities was ¥18,628,464.93, a turnaround from -¥5,603,689.48 in Q3 2021[26] Shareholder Information - The company’s total equity attributable to shareholders at the end of Q3 2022 was CNY 1,871,803,947.26, a growth of 7.43% compared to the end of the previous year[4] - The total equity attributable to shareholders increased to ¥1,871,803,947.26, up from ¥1,742,292,532.40, a growth of 7.4%[23] - The total number of common shareholders at the end of the reporting period is 33,824[15] - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[15] Other Income and Expenses - The company’s other income increased by 208.05% year-on-year, mainly due to a tax reward received from the local government amounting to CNY 2,844,100.00[9] - Research and development expenses for the period were ¥33,008,550.96, compared to ¥26,339,208.61 in the previous period, indicating a 25.4% increase[23] - Other comprehensive income after tax decreased to -¥1,912,591.42 from ¥7,803,735.27, reflecting a significant decline[24] - The total comprehensive income for the period was ¥128,161,417.45, compared to ¥121,296,601.31 in the previous period, an increase of 5.7%[24] Audit Information - The company did not undergo an audit for the Q3 report[28]

证券代码：002412 证券简称：汉森制药 公告编号：2022-026 湖南汉森制药股份有限公司 关于参加 2022 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 为进一步加强与广大投资者的沟通交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南证监局、湖南省上市公司 协会与深圳市全景网络有限公司联合举办的"湖南辖区上市公司投资者网上接待 日"活动，现将有关事项公告如下： 本次网上接待日活动将采取网络远程的方式举行，投资者可以登录"全景路 演"网站（http://rs.p5w.net），参与本次投资者网上接待日活动，活动时间为 2022 年 09 月 29 日（星期四）下午 15：30 至 17：00。 届时公司董事会秘书、证券事务代表将通过网络在线问答互动的形式，就投 资者关心的问题进行沟通与交流。 欢迎广大投资者积极参与。 | --- | --- | --- | |-------|-------|-------------------------------| | | | 湖南 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥462,679,892.19, representing a 4.42% increase compared to ¥443,087,312.44 in the same period last year[17]. - The net profit attributable to shareholders was ¥78,881,640.51, an increase of 11.67% from ¥70,635,880.51 in the previous year[18]. - Basic earnings per share rose to ¥0.1568, reflecting an increase of 11.68% from ¥0.1404 in the previous year[18]. - The total profit for the same period was CNY 89.18 million, up 11.59% compared to the previous year[28]. - The company's total revenue for the first half of 2022 was CNY 462.68 million, representing a year-on-year increase of 4.42%[28]. - The company's total profit for the first half of 2022 was CNY 89,176,229.11, compared to CNY 79,911,966.72 in the same period of 2021, indicating a growth of around 11.6%[124]. - The company's total comprehensive income for the first half of 2022 was CNY 80,297,117.33, compared to CNY 69,801,420.66 in the same period of 2021, reflecting an increase of approximately 15%[125]. Cash Flow and Financial Position - The net cash flow from operating activities decreased by 52.68%, amounting to ¥54,750,153.07 compared to ¥115,705,962.98 in the same period last year[18]. - The net cash flow from operating activities decreased to ¥54,750,153.07 in the first half of 2022, down 52.7% from ¥115,705,962.98 in the same period of 2021[130]. - The net increase in cash and cash equivalents was CNY 25,966,831.51, a decline of 66.82% from CNY 78,270,772.81 in the previous year[32]. - The company's cash and cash equivalents increased to ¥116,278,277.21 from ¥90,311,445.70 at the beginning of the year, representing a growth of approximately 29%[116]. - The company's total assets at the end of the reporting period were ¥2,203,980,410.94, a 4.39% increase from ¥2,111,282,192.35 at the end of the previous year[18]. - The total liabilities increased to CNY 381,390,761.21 as of June 30, 2022, compared to CNY 368,989,659.95 at the start of the year, marking an increase of about 3.6%[118]. Investment and R&D - Research and development expenses increased by 29.52% to CNY 23,042,775.48, compared to CNY 17,791,098.85 in the same period last year[32]. - The company has committed to continuous investment in drug research and development, with a focus on the consistency evaluation of generic drugs, despite the high costs and risks involved[60]. - The company plans to enhance its research and development capabilities to innovate new technologies and products[137]. - The company aims to improve operational efficiency through potential mergers and acquisitions in the upcoming fiscal year[142]. Product and Market Strategy - The company's main product, Si Mo Tang oral liquid, is a unique product in the market and has been included in the national medical insurance directory[28]. - The marketing strategy has been optimized to adapt to industry changes, focusing on specialized operations across different market segments[27]. - The company plans to diversify its product offerings to support sustainable profit growth in the future[28]. - The company plans to expand its market presence and invest in new product development to drive future growth[141]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding future plans and development strategies[3]. - The company faces risks related to raw material procurement, particularly for traditional Chinese medicine ingredients, which may be affected by environmental factors and resource scarcity[60]. - The company will strengthen quality control measures and adhere to environmental regulations to mitigate production-related risks[61]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[70]. Corporate Governance and Structure - The company has not engaged in any related party transactions during the reporting period[82]. - The company has not reported any significant financial indicators affected by share changes[101]. - The company has five subsidiaries included in the consolidation scope as of June 30, 2022, indicating a stable operational structure[150]. - The financial report was approved by the fifth board of directors on August 26, 2022, ensuring compliance with regulatory standards[150]. Future Outlook - Future guidance indicates a cautious outlook with expected revenue growth of 2.3% for the next half-year[141]. - The company aims to optimize its product structure and actively seek acquisition opportunities to diversify its product offerings and create new profit growth points[61].

Financial Performance - The company's revenue for Q1 2022 was CNY 248,851,389.62, representing a 5.72% increase compared to CNY 235,387,600.31 in the same period last year[3] - Net profit attributable to shareholders was CNY 51,824,070.34, up 13.32% from CNY 45,731,537.24 year-on-year[3] - The total operating revenue for Q1 2022 was CNY 248,851,389.62, an increase of 5.8% compared to CNY 235,387,600.31 in Q1 2021[18] - The net profit for Q1 2022 reached CNY 51,824,070.34, representing a growth of 13.5% from CNY 45,731,537.24 in the same period last year[19] - The total comprehensive income for Q1 2022 was CNY 49,185,657.62, compared to CNY 41,997,646.77 in the same period last year, marking an increase of 17.5%[20] - The company's diluted earnings per share increased by 13.31% to CNY 0.1030 from CNY 0.0909 in the previous year[3] - The basic earnings per share for Q1 2022 was CNY 0.1030, an increase from CNY 0.0909 in Q1 2021[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 37.91% to CNY 44,016,378.08, down from CNY 70,886,845.47 in the previous year[3] - The cash inflow from operating activities was CNY 249,825,439.23, compared to CNY 242,374,291.24 in the previous year, indicating a growth of 3.0%[21] - The total cash and cash equivalents at the end of Q1 2022 amounted to ¥90,759,367.83, down from ¥133,986,934.55 at the end of Q1 2021[23] - The company reported a total cash outflow from operating activities of ¥205,809,061.15, which is an increase from ¥171,487,445.77 in Q1 2021[23] - The company reported a decrease in cash and cash equivalents by 98.53%, totaling CNY 1,000,000.00 compared to the previous year[8] Research and Development - R&D expenses increased by 35.74% to CNY 8,598,000.00, primarily due to enhanced investment in the consistency evaluation of isoniazid tablets and iodinated contrast agents[6] - Research and development expenses increased to CNY 8,682,027.43, up 35.7% from CNY 6,396,211.92 in Q1 2021[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,132,384,519.04, a 1.00% increase from CNY 2,111,282,192.35 at the end of the previous year[3] - The total current assets are RMB 560,644,902.53, up from RMB 535,410,439.63 at the beginning of the year, reflecting a growth of approximately 4.3%[15] - The accounts receivable increased to RMB 245,321,781.67 from RMB 207,401,998.50, indicating a growth of about 18.3%[15] - The total liabilities decreased to CNY 340,906,329.02 from CNY 368,989,659.95 year-over-year, reflecting a reduction of approximately 7.6%[17] - The company's short-term borrowings decreased to RMB 102,901,468.00 from RMB 131,791,855.05, a reduction of approximately 22%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,670[10] - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[10] - The total number of shares held by the top ten unrestricted shareholders includes 212,006,189 shares held by Hainan Hansen Holdings[10] Other Financial Activities - The company completed the registration of business changes and received a new business license on January 8, 2022[12] - The company plans to invest up to RMB 10 million as a limited partner in an industry investment fund with Shenzhen Rongyu Capital Management Co., Ltd.[12] - The company recorded a total of CNY 551,165.57 in non-recurring gains and losses for the reporting period[5] Operating Costs - The total operating costs for Q1 2022 were CNY 199,935,352.92, slightly up from CNY 197,880,670.79 in Q1 2021[18] - The company reported a decrease in sales expenses to CNY 105,570,433.08 from CNY 108,676,129.07 year-over-year, a reduction of 2.0%[18] Audit and Reporting - The company did not conduct an audit for the Q1 2022 report[24] - The report was released by the board of directors on April 28, 2022[25]

Financial Performance - The company's operating revenue for 2021 was ¥891,835,182.38, representing a 20.32% increase compared to ¥741,237,325.38 in 2020[19] - The net profit attributable to shareholders for 2021 was ¥134,848,862.26, which is a 27.04% increase from ¥106,146,369.35 in 2020[19] - The net profit after deducting non-recurring gains and losses was ¥131,494,576.68, up 35.13% from ¥97,309,903.36 in 2020[19] - The net cash flow from operating activities increased by 29.99% to ¥212,536,478.83 from ¥163,505,165.65 in 2020[19] - The total assets at the end of 2021 were ¥2,111,282,192.35, an increase of 11.79% from ¥1,888,641,664.49 at the end of 2020[19] - The net assets attributable to shareholders increased by 9.25% to ¥1,742,292,532.40 from ¥1,594,720,660.84 at the end of 2020[19] - The basic earnings per share for 2021 was ¥0.2680, a 27.07% increase from ¥0.2109 in 2020[19] - The weighted average return on equity for 2021 was 8.06%, up from 6.71% in 2020[19] Revenue Breakdown - The company's total revenue for Q1 was ¥235.39 million, Q2 was ¥207.70 million, Q3 was ¥216.83 million, and Q4 was ¥231.92 million, showing a stable performance throughout the year[23] - The net profit attributable to shareholders for Q1 was ¥45.73 million, Q2 was ¥24.90 million, Q3 was ¥42.86 million, and Q4 was ¥21.36 million, indicating fluctuations in profitability[23] - The net cash flow from operating activities for Q1 was ¥70.89 million, Q2 was ¥44.82 million, Q3 was ¥63.16 million, and Q4 was ¥33.67 million, reflecting a strong cash generation capability in the first half of the year[23] Product and Market Development - The company is engaged in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine, chemical drugs, and medical preparations, with plans to expand into the health care sector[31] - The company has introduced several key products, including Qumotang Oral Liquid and Ginkgo Leaf Capsules, targeting various health issues such as digestive disorders and cardiovascular diseases[31] - The pharmaceutical industry is experiencing rapid growth due to factors such as increased disposable income, healthcare reforms, and an aging population, which are expected to drive demand for medical products[29] - The company is adapting to significant policy changes in the pharmaceutical sector, including the national volume-based procurement policy aimed at promoting innovation and high-quality development[30] - The company has maintained a focus on research and development to enhance its product offerings and meet evolving market demands[31] Strategic Initiatives - The company has established a marketing system that includes hospital, grassroots, chain, distribution, and e-commerce sales channels to enhance brand promotion[38] - The company is expanding into the health and medical care sector with the establishment of the Hunan Hansen Health Industry Park[37] - The company has implemented a procurement management system to control costs and ensure quality, with a focus on supplier evaluation and market price tracking[35] - The company is committed to continuous product development and market support, aiming for sustainable profit growth[37] Governance and Compliance - The company emphasizes the importance of information disclosure and investor relations management, ensuring timely and accurate information dissemination to all investors[102] - The company maintains a fully independent business system, with no shared financial or operational resources with its controlling shareholders[104] - The company has established a dedicated investor relations section on its website to facilitate communication with investors[103] - The company has a clear structure for its board of directors, with all members fulfilling their duties in accordance with relevant laws and regulations[101] - The company has a dedicated internal audit department that supervises daily operations and major related transactions[103] Risk Management - The management has outlined potential risks and countermeasures in the future development outlook section of the report[4] - The company faces risks related to policy changes in the pharmaceutical industry, with significant impacts from national regulations and healthcare reforms[93] - The company plans to continuously monitor the pandemic situation and adjust product sales strategies to minimize adverse impacts[96] Employee and Corporate Culture - The company has invested in employee training and development, establishing a performance management system to motivate staff and improve overall quality[44] - The company is focused on enhancing corporate culture and talent management to improve employee engagement and retention[92] - The company has maintained a strong focus on employee rights, providing a safe working environment and comprehensive social insurance[141] Financial Management - The company has implemented a strict remuneration system for its directors and senior management based on their roles and performance[116] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to RMB 3.39 million[117] - The company has established a comprehensive internal control system in accordance with relevant laws and regulations, covering various management aspects[133] Investment and Acquisitions - The company has established a new subsidiary, Hunan Shanshui Kangcheng Real Estate Development Co., Ltd., with a registered capital of 50 million yuan, fully owned by Hunan Hansen Health Industry Co., Ltd.[152] - The company acquired 80% of Yunnan Yongzitang Pharmaceutical Co., Ltd. for CNY 282 million using over-raised funds[79] - The company plans to increase its investment in its wholly-owned subsidiary by RMB 138 million to support the health industry project[178] Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including promoting green office practices and resource recycling[140] - The company has reported no environmental penalties during the reporting period, demonstrating its commitment to environmental protection[139] - The company emphasizes environmental protection and sustainable development, continuously improving its environmental management to meet industry requirements[142]

Financial Performance - The company's revenue for Q3 2021 was ¥216,830,821.90, representing a 3.17% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥42,856,985.53, a 35.95% increase year-over-year[4] - The basic earnings per share for Q3 2021 was ¥0.0852, reflecting a 36.10% increase compared to the same period last year[4] - Total operating revenue for Q3 2021 reached CNY 659.92 million, a 26.4% increase from CNY 521.90 million in the same period last year[23] - Net profit for Q3 2021 was CNY 113.49 million, representing a 33.9% increase compared to CNY 84.75 million in Q3 2020[24] - Earnings per share for Q3 2021 were CNY 0.2255, compared to CNY 0.1684 in the same quarter last year, reflecting a 34% increase[24] - The total comprehensive income for Q3 2021 increased by 43.37%, amounting to an increase of ¥36,691,119.89 compared to the previous year[11] - The company reported a total comprehensive income of CNY 121.30 million for Q3 2021, compared to CNY 84.61 million in Q3 2020, marking a 43.3% increase[24] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥2,043,914,429.74, an increase of 8.22% from the end of the previous year[4] - The company's current assets totaled CNY 575,472,832.57, compared to CNY 527,456,165.16 at the end of 2020, indicating an increase of about 9.1%[20] - The total non-current assets reached CNY 1,468,441,597.17, compared to CNY 1,361,185,499.33 at the end of 2020, which is an increase of about 7.9%[20] - Total liabilities as of Q3 2021 were CNY 327.90 million, an increase from CNY 293.92 million in the same period last year[23] - The company’s total liabilities decreased by 65.11% in contract liabilities, reflecting a reduction in pre-received customer payments[8] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥178,868,988.40, showing a 50.56% increase[4] - The company experienced a 50.56% increase in net cash flow from operating activities, primarily due to increased cash received from sales[11] - Cash flow from operating activities for Q3 2021 was CNY 178.87 million, an increase of 50.6% from CNY 118.80 million in Q3 2020[26] - The net cash flow from investing activities was -150,779,901.61, compared to -19,680,203.90 in the previous year, indicating a significant increase in cash outflows for investments[27] - Cash inflows from financing activities totaled 130,153,195.20, up from 110,191,243.32 year-over-year, reflecting an increase in borrowings[27] - The net cash flow from financing activities was -5,603,689.48, an improvement from -93,931,660.42 in the same period last year, showing reduced cash outflows for debt repayment and dividends[27] - The total cash and cash equivalents at the end of the period amounted to 126,046,267.58, compared to 121,797,903.72 at the end of the previous year, indicating a slight increase[27] Investments and Expenses - The company reported a 43.40% increase in investment income, amounting to an increase of ¥16,481,080.16 compared to the previous year[10] - Research and development expenses for Q3 2021 amounted to CNY 26.34 million, up 19.5% from CNY 21.95 million in the previous year[23] - Total operating costs for Q3 2021 were CNY 593.90 million, up 25.3% from CNY 474.33 million in Q3 2020[23] Compliance and Governance - The company has acknowledged the need for corrective measures following regulatory scrutiny, emphasizing its commitment to compliance and transparency[16] - The company held a board meeting to address prior accounting errors, ensuring adherence to accounting standards and improving financial reporting accuracy[17] - The third quarter report was not audited, which may affect the reliability of the financial data presented[30] Other Comprehensive Income - The company’s other comprehensive income increased by 90.21%, amounting to an increase of ¥7,803,735.27 compared to the previous year[9] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23]

证券代码：002412 证券简称：汉森制药 公告编号：2021-045 湖南汉森制药股份有限公司 关于参加 2021 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性 陈述或者重大遗漏。 为进一步加强与广大投资者的沟通交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南证监局主办、湖南省上市 公司协会与深圳市全景网络有限公司协办的"湖南辖区上市公司投资者网上集体 接待日" 活动，现将有关事项公告如下： 本次网上集体接待日活动将采取网络远程的方式举行，投资者可以登录"全 景·路演天下"网站（http://rs.p5w.net），参与本次投资者网上集体接待日活动， 活动时间为 2021 年 09 月 24 日（星期五）下午 15：00 至 17：00。 届时公司董事会秘书等相关人员将通过网络在线问答互动的形式，就投资者 关心的问题进行沟通与交流。 欢迎广大投资者积极参与。 | --- | --- | --- | |-------|-------|-------------------------------| ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 443,087,312.44, representing a 42.14% increase compared to CNY 311,730,353.40 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 70,635,880.51, up 32.70% from CNY 53,230,273.07 in the previous year[18]. - The net cash flow from operating activities reached CNY 115,705,962.98, a significant increase of 206.65% compared to CNY 37,731,814.71 in the same period last year[18]. - The total assets at the end of the reporting period were CNY 2,037,929,328.35, reflecting a 7.90% increase from CNY 1,888,641,664.49 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased by 4.38% to CNY 1,664,522,081.50 from CNY 1,594,720,660.84 at the end of the previous year[18]. - The basic earnings per share for the first half of 2021 were CNY 0.1404, a 32.70% increase from CNY 0.1058 in the same period last year[18]. - Operating profit reached 79.84 million yuan, up 23.38% compared to the same period last year[30]. - The company reported a total of CNY 1,364,669.87 in non-recurring gains and losses during the reporting period[22]. Cash Flow and Financial Management - The company reported a significant increase in cash and cash equivalents, which rose by 354.43% to ¥78,270,772.81, reflecting improved operational cash flow[36]. - The company's cash and cash equivalents increased by 75.58% to ¥181.83 million compared to the beginning of the year[46]. - The cash flow from operating activities generated a net amount of CNY 115,705,962.98, significantly higher than CNY 37,731,814.71 in the previous year[132]. - The company received CNY 100,000,000.00 in borrowings during the first half of 2021, compared to CNY 60,000,000.00 in the same period of 2020[132]. - The company has maintained a cash flow that is relatively abundant, allowing for normal production and operation without significant project expenditures[84]. Market and Product Development - The company is gradually expanding into the health industry and medical care sectors[26]. - The company’s main products include traditional Chinese medicine, chemical drugs, and medical preparations, with a focus on various therapeutic functions[26][27][28][29]. - The company plans to diversify its product offerings, which is expected to support sustained profit growth in the future[36]. - The company is focused on enhancing its health industry park project, reflecting its strategic growth initiatives[94]. - The company plans to continue expanding its market presence and investing in new product development in the upcoming quarters[145]. Risks and Compliance - The company faces risks related to policy changes in the pharmaceutical industry, with significant reliance on its leading product, Si Mo Tang Oral Liquid, which accounts for over 50% of revenue[54]. - The company is actively taking measures to mitigate risks, including optimizing product structure and enhancing market development efforts[57]. - The company plans to strengthen product quality control and adhere to environmental regulations to manage production-related risks[55]. - The company has not engaged in targeted poverty alleviation or rural revitalization efforts during the reporting period, nor are there any subsequent plans[66]. - The company has committed to ensuring the legality and fairness of related party transactions, with strict adherence to relevant laws and regulations[70]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 23,678[100]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares, totaling 212,006,189 shares[100]. - The total number of shares is 503,200,000, with 1.90% being limited sale condition shares and 98.10% being unrestricted sale condition shares[98]. - The number of shares pledged by the largest shareholder is 135,175,000[100]. - The company has not experienced any changes in its controlling shareholder during the reporting period[103]. Accounting and Financial Reporting - The financial report was approved on August 26, 2021, by the 10th meeting of the 5th Board of Directors[151]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect the true financial condition as of June 30, 2021[156]. - The company’s financial statements are prepared based on the accrual basis of accounting, reflecting actual transactions and events[153]. - The company will reassess control definitions if relevant facts and circumstances change, impacting the consolidation scope[166]. - The company applies the equity method for investments in joint ventures, recognizing its share of assets and liabilities[169]. Inventory and Asset Management - Inventory levels increased to CNY 88,583,527.48 from CNY 84,428,766.98, showing a growth of approximately 4.79%[113]. - The company recognizes inventory impairment when the net realizable value is lower than the cost, with provisions made based on the difference for each inventory item[187]. - Non-current assets totaled CNY 1,440,270,094.77, an increase from CNY 1,361,185,499.33, indicating a growth of approximately 5.81%[114]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[80]. Research and Development - Research and development expenses increased by 34.06% to ¥17,791,098.85, primarily due to higher costs associated with the consistency evaluation of iodinated contrast agents[35]. - Research and development expenses for the first half of 2021 were CNY 17.79 million, up 33.93% from CNY 13.27 million in the first half of 2020[121]. Other Financial Metrics - The company's financial expenses decreased by 22.14% to ¥2,548,339.80, indicating improved financial management[35]. - The gross profit margin for the pharmaceutical industry was 72.62%, an increase of 1.40% compared to the previous year[40]. - The company reported a total comprehensive income of CNY 68,480,106.67, compared to CNY 49,994,258.63 in the same period last year, reflecting a growth of 37.0%[128].

Financial Performance - The company's operating revenue for 2020 was ¥741,237,325.38, a decrease of 16.48% compared to ¥887,490,963.28 in 2019[16] - The net profit attributable to shareholders for 2020 was ¥106,146,369.35, down 34.63% from ¥162,377,707.21 in 2019[16] - The net profit after deducting non-recurring gains and losses was ¥97,309,903.36, a decline of 36.95% from ¥154,338,124.68 in 2019[16] - The basic earnings per share for 2020 was ¥0.2109, a decrease of 34.65% compared to ¥0.3227 in 2019[16] - The total non-operating income and expenses, excluding the aforementioned items, resulted in a loss of ¥405,941.47 in 2020, compared to a profit of ¥1,680,205.33 in 2019[23] - The total non-recurring profit and loss for the company in 2020 was ¥8,836,465.99, slightly up from ¥8,039,582.53 in 2019[23] - The company's revenue for the pharmaceutical industry was approximately ¥739.97 million, a decrease of 16.50% compared to the same period last year[49] - The gross profit margin for the pharmaceutical industry was 70.27%, down 3.51% year-on-year[49] Assets and Liabilities - The total assets at the end of 2020 were ¥1,888,641,664.49, an increase of 0.30% from ¥1,882,905,804.71 at the end of 2019[16] - The net assets attributable to shareholders at the end of 2020 were ¥1,594,720,660.84, up 4.23% from ¥1,529,977,688.84 at the end of 2019[16] - The company's deferred income tax assets increased by 35.43%, reflecting an increase in government subsidies related to assets[34] - Long-term equity investments rose to ¥628.39 million, representing 33.27% of total assets, an increase of 2.54% from the previous year[64] - Other receivables increased dramatically by 1992.11% to ¥35.15 million, primarily due to a land guarantee payment of ¥23.60 million[64] Cash Flow - The net cash flow from operating activities for 2020 was ¥163,505,165.65, a decrease of 2.55% from ¥167,788,107.51 in 2019[16] - Operating cash inflow for 2020 was ¥928.73 million, a decrease of 4.88% compared to ¥976.33 million in 2019[60] - Investment cash inflow increased by 74.60% to ¥35.75 million, while investment cash outflow surged by 103.83% to ¥154.32 million, resulting in a net cash flow from investment activities of -¥118.57 million, a decline of 114.67%[60][61] - Net increase in cash and cash equivalents was -¥13.05 million, a significant drop of 138.50% from an increase of ¥33.89 million in 2019[61] Business Operations - The company's main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations, with a gradual expansion into the health and medical care sectors[26] - The product "Si Mo Tang Oral Liquid" is the only compound gastrointestinal motility traditional Chinese medicine product in the market, showing significant therapeutic effects, especially in post-operative recovery[30] - In 2020, the company faced a decline in sales volume due to the pandemic, leading to a decrease in operating income and net profit[30] - The marketing strategy includes a diversified approach with hospital promotion, grassroots promotion, chain promotion, distribution promotion, and controlled marketing[30] - The company has established a procurement management system to ensure quality and cost-effectiveness in raw material sourcing, adapting to market changes[30] Research and Development - Research and development expenses amounted to ¥31.63 million, representing 4.27% of total revenue, an increase from 3.79% in the previous year[59] - The number of R&D personnel increased by 32.28% to 209, accounting for 13.83% of the total workforce[59] - The company achieved a significant increase in the capitalized amount of R&D expenses by 139.74% compared to the previous year[59] Strategic Initiatives - The company plans to focus on innovation-driven development, launching new specifications and formulations for its key products, and enhancing production quality control technology[85] - The company aims to achieve a stable growth in performance in 2021 while ensuring the "four safety" principles, emphasizing quality improvement and operational efficiency[86] - The company intends to extend its business into health and medical care sectors, including the construction of traditional Chinese medicine GAP bases and elderly care services[85] - The company aims to rank among the top 50 pharmaceutical companies in China, focusing on product advantages and core competitiveness[85] Governance and Compliance - The company has established a sound internal control system to protect the rights of shareholders and creditors, ensuring compliance with relevant laws and regulations[131] - The company emphasizes employee rights protection, providing a good working environment and signing labor contracts with all employees[131] - The company has implemented a performance evaluation system and conducts regular health check-ups for employees[131] - The company has established a robust internal audit system to supervise daily operations and major transactions[181] Shareholder Information - The total share capital is 503,200,000 shares, with a cash dividend of RMB 0.75 per 10 shares for the 2019 annual equity distribution[136] - The company has not distributed any cash dividends in 2020 and plans to roll over the undistributed profits to meet future operational funding needs[98] - The company has committed to not distributing cash dividends or bonus shares for the current fiscal year[99] Risk Management - The company has indicated potential risks in its future development outlook, which investors should be aware of[4] - The company faces risks from policy changes in the pharmaceutical industry, including stricter drug approval and quality supervision regulations[88] - The company is committed to improving product quality control and adhering to safety and environmental standards to mitigate production risks[91]

Financial Performance - The company's operating revenue for Q1 2021 was CNY 235,387,600.31, representing a 35.01% increase compared to CNY 174,351,660.96 in the same period last year[7]. - Net profit attributable to shareholders was CNY 45,731,537.24, up 23.79% from CNY 36,943,574.88 year-on-year[7]. - Basic earnings per share were CNY 0.0909, reflecting a 23.84% increase from CNY 0.0734 in the same quarter last year[7]. - The company's operating profit for Q1 2021 was CNY 51.78 million, an increase of 20.3% from CNY 43.02 million in the same period last year[44]. - The total profit for Q1 2021 was CNY 51.79 million, an increase of 21.6% from CNY 42.54 million in Q1 2020[44]. - The total comprehensive income for Q1 2021 was CNY 41.99 million, a decrease of 15.5% from CNY 49.69 million in Q1 2020[42]. Cash Flow - The net cash flow from operating activities reached CNY 70,886,845.47, a significant increase of 1,325.96% compared to a negative cash flow of CNY 5,782,168.59 in the previous year[7]. - The cash flow from operating activities for Q1 2021 was CNY 70.89 million, a significant improvement compared to a negative cash flow of CNY 5.78 million in the same period last year[49]. - The net increase in cash and cash equivalents was CNY 13,213,916.83, a growth of 76.77%, attributed to the increase in net cash flow from operating activities[17]. - The total cash inflow from operating activities was CNY 191,560,827.13, compared to CNY 155,880,859.60 in the previous year, marking an increase of approximately 22.9%[51]. - The net cash flow from investing activities was -CNY 14,063,709.06, compared to -CNY 405,308.11 in the previous year, showing increased investment outflows[53]. - The net cash flow from financing activities was -CNY 31,612,220.24, contrasting with a positive net cash flow of CNY 28,495,809.77 in the same period last year[53]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,921,371,947.38, a 1.73% increase from CNY 1,888,641,664.49 at the end of the previous year[7]. - The company's total liabilities decreased to CNY 304,748,285.27 from CNY 310,340,450.87, a reduction of approximately 1.9%[37]. - The equity attributable to shareholders increased to CNY 1,668,458,110.60 from CNY 1,629,570,165.96, indicating a growth of about 2.4%[37]. - Cash and cash equivalents increased to CNY 89,794,057.91 from CNY 71,947,021.43, marking a rise of approximately 24.9%[34]. - Accounts receivable rose to CNY 204,273,523.74 from CNY 166,163,659.43, reflecting an increase of about 22.9%[34]. - The ending balance of other current assets decreased by CNY 22,307,819.74, a decline of 91.85%, primarily due to the offset of prepaid VAT by the parent company during the reporting period[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,411[11]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares, amounting to 212,006,189 shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Expenses and Costs - Operating costs rose by CNY 16,819,782.53, a growth of 36.90%, corresponding to the increase in sales revenue[15]. - Sales expenses increased by CNY 31,580,411.32, a growth of 40.96%, mainly due to increased sales activities during the reporting period[16]. - Research and development expenses for Q1 2021 amounted to CNY 5.22 million, up from CNY 4.37 million in Q1 2020, indicating a focus on innovation[44]. - The company reported a research and development expense of CNY 6,396,211.92, compared to CNY 5,184,895.94 in the previous year, reflecting an increase of approximately 23.3%[40]. Other Income and Gains - The company reported non-recurring gains and losses totaling CNY 788,560.30 for the reporting period[8]. - Other income increased by CNY 263,173.12, a growth of 41.37%, primarily due to a government subsidy received for the smart manufacturing system[16]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[44].